NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/10/2023
Back to search
Official data from USPTO
LOCUS BIOSCIENCES
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
LOCUS BIOSCIENCES
ST13
US500000097243633Class
42
Filing
97243633
Registration
6949794
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
13
Latest update
01/10/2023
Trademark type
Word
Nice classes
42
Filing date
01/28/2022
Registration date
01/10/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/10/2023
Last transaction
01/10/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
First use anywhere
06/08/2015
First use in commerce
01/02/2019
Drawing code
4
Owner type
03
Owner location
Morrisville, NC, US
Examiner
JOHNSON, CLINTON J
Law office
L70
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Locus Biosciences, Inc.
Representatives
EVA GULLICK FRONGELLO SMITH ANDERSON BLOUNT DORSETT MITCHELL & JERNIGAN
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Pharmaceutical research and development; research and development in pharmacology for the purpose of targeting and destroying bacteria; medical research for use in treating antibiotic-resistant bacterial infections and microbiome-related disorders; medical and scientific research; pharmaceutical research in the field of engineered bacteriophage; pharmaceutical research using engineered therapeutics for use in antibacterial drug development; pharmaceutical researchresearch relating to engineered bacteriophage platforms for improving pharmacological properties; pharmaceutical researchresearch relating to engineered bacteriophages for use in connection with a wide variety of therapeutic agents
Publications
History of USPTO decisions and trademark events.
13 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
01/10/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/25/2022
PUBO
PUBLISHED FOR OPPOSITION
10/25/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/05/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/21/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
09/21/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
09/21/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
09/21/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
09/21/2022
DOCK
ASSIGNED TO EXAMINER
09/20/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/01/2022
NWAP
NEW APPLICATION ENTERED
02/01/2022
Continuous trademark protection
Get notified about every new filing that threatens LOCUS BIOSCIENCES or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.